French microbiologist Emmanuelle Charpentier, who was named a co-winner of the second Tang Prize in biopharmaceutical science on Sunday for her work in the development of CRISPR/Cas9, said she hopes the genome editing technology can be used to treat currently incurable conditions.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Science & Tech
Taiwan's ITRI joins top global program as cybersecurity assessor
01/29/2026 12:03 PM - Politics
No need to 'pick a side' between U.S. and China: KMT chair
01/29/2026 11:28 AM - Business
Taiwan shares open higher
01/29/2026 09:12 AM - Society
Taiwan headline news
01/29/2026 08:26 AM - Business
MOEA approves Nvidia HQ investment on eve of Jensen Huang visit
01/28/2026 08:54 PM